STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
1. STRM.BIO secures ARPA-H contract for immune cell engineering. 2. Non-viral delivery technologies could advance gene therapy approaches.